ormeloxifene

10/22/2022 - "The present study aims to compare the cost-effectiveness, safety, efficacy, and health-related quality of life of ormeloxifene with medroxyprogesterone acetate in women with non-structural abnormal uterine bleeding. "
10/01/2016 - "The purpose of this study was to compare the effects of ormeloxifene with medroxyprogesterone acetate in patients with abnormal uterine bleeding. "
10/01/2016 - "Comparative Study of Ormeloxifene and Medroxyprogesterone Acetate in Abnormal Uterine Bleeding."
10/22/2022 - "Conclusions: The study concludes that both medroxyprogesterone acetate and ormeloxifene are safe and efficacious in controlling abnormal uterine bleeding, but ormeloxifene was the better of the two in terms of cost effectiveness, reduction in pictorial blood loss assessment score, endometrial thickness, bleeding duration (days), increase in haemoglobin concentration (g/dL) and improvement in the quality of life."
12/01/2016 - "Efficacy of ormeloxifene versus oral contraceptive in the management of abnormal uterine bleeding due to uterine leiomyoma."

01/01/2022 - "The studies proved effective cytotoxicity of Ormeloxifene on cancer cell lines with lower TGI, GI50 and LC50 values which are significantly comparable. "
01/21/2020 - "Overall, this study confirms possible novel nanoformulation(s) of ormeloxifene to be evolved as a new therapeutic modality for cancer treatment."
01/21/2020 - "Our aim is to develop nanoformulation(s) of ormeloxifene to improve its targeted delivery in tumor cells. "
10/01/2017 - "These molecular effects of ormeloxifene were also observed in excised tumor tissues as shown by immunohistochemistry analysis. "
10/01/2017 - "In addition, ormeloxifene treatment significantly (P < 0.01) regressed the prostate tumor growth in the xenograft mouse model while administered through intraperitoneal route (250 μg/mouse, three times a week). "

03/01/2013 - "Ormeloxifene showed significant efficacy for treating breast pain and nodularity."
03/01/2013 - "A randomized, double-blind, placebo-controlled trial of ormeloxifene in breast pain and nodularity."
07/01/2022 - "A total of 113 consecutive women with mastalgia were randomized to the GLA group (Group 1, n = 39 women), Ormeloxifene (Group 2, n = 36) and Placebo (Group 3, n = 38). "
12/01/2018 - "Newer agents (Ormeloxifene) currently being used for mastalgia in India could be considered in the developed world."
07/01/2022 - "The role of Ormeloxifene in mastalgia needs further evaluation before recommending it as preferred therapy."

07/01/2022 - "In this study Ormeloxifene and GLA were not superior to placebo for pain relief in mastalgia. "
11/01/2021 - "Ormeloxifene (centchroman) is an antiestrogenic drug which is shown to have effect in reducing the pain in mastalgia patients and the size of fibroadenoma. "
10/22/2022 - "Health-related quality of life improved in the ormeloxifene group more than the medroxyprogesterone group, which was evidenced by SF-36 scale parameters (physical function, energy/fatigue and pain) that changed from 24.39, 12.99, 6.25 to 28.95, 18, 9 and from 25.41, 13.6, 7.1 to 27.02, 16, 8.3 in the ormeloxifene and medroxyprogesterone acetate groups, respectively. "

11/01/2013 - "This study was carried out to evaluate the efficacy of Ormeloxifene in the pharmacological management of dysfunctional uterine bleeding. "
11/01/2013 - "A study of efficacy of ormeloxifene in the pharmacological management of dysfunctional uterine bleeding."
11/01/2013 - "The results in this study indicate that Ormeloxifene, a non-steroidal, non-hormonal agent, provides effective and favourable pharmacological management option with least side effects, suitable for the treatment of dysfunctional uterine bleeding."
01/01/2013 - "Ormeloxifene can be used asa effective drug in the treatment of Dysfunctional uterine bleeding."